In the previous year, 38 medicines with new active ingredients came to the European market. The pharmaceutical industry in Europe has increasingly invested in research and development in recent years, but the number of clinical studies has decreased.
“Current statistics show that the number of clinical studies throughout Europe is decreasing and is also noticeable in Austria with a minus of more than ten percent. At the same time, masses are being invested in clinical research in the US and China,” said Leif Moll, president of the forum of investigating the pharmaceutical industry (Fopi).
However, the result of research is still remarkable. The 38 approved medicines in the previous year are partly due to oncology. Part of the immune system specifically dampens car -immune diseases. There are also new vaccines and new drugs for diabetes.
New active ingredient of breast cancer
“This is particularly remarkable, for example a new ingredient for breast cancer that is used for commonly occurring breast cancer when common therapies no longer strike,” said Günter Waxenecker, head of the medical market authorities of the diet (Agency for Nutrition Security). The age is involved in expert teams and approval procedures.
Infectiologist Heinz Burgmann pointed out on Tuesday that antibiotic resistance is now a major threat to public health. According to estimates, around 35,800 people in Europe die annually of infections with resistant bacteria. That is why there is a need for new effective antibiotics in addition to the responsible treatment of medicinal products.
Source: Krone
I am an experienced and passionate journalist with a strong track record in news website reporting. I specialize in technology coverage, breaking stories on the latest developments and trends from around the world. Working for Today Times Live has given me the opportunity to write thought-provoking pieces that have caught the attention of many readers.
